Two new Neutrogena facial sunscreens incorporate bemotrizinol, the first new sunscreen active ingredient added to the US OTC monograph in decades.
News|Articles|June 30, 2026
- Dermatology Times, June 2026 (Vol. 47. No. 06)
- Volume 47
- Issue 06
Dermatology Times June 2026 Print Recap
Author(s)Marie Bosslett, Assistant Editor
Learn more about the in-depth topics covered in the June 2026 print issue of Dermatology Times.
Advertisement
Advertisement
The June issue of Dermatology Times includes a collection of thought-provoking articles and topics as we examine emerging evidence for ruxolitinib cream in hidradenitis suppurativa, explore the exciting update in US sunscreen formulations, review the Sun Bus’ community impact, and more.
Related to this article
From emerging therapies to earlier intervention and psychosocial support, Dermatology Times looks back at key alopecia areata developments in 2026.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
Advertisement
Advertisement